The FDA has accepted the company’s Abbreviated New Drug Application for KETARX™ (racemic ketamine). The goal date for this priority original ANDA of...
Non-profit TheraPsil announces launching of MDMA therapy training program. The post TheraPsil Unveils MDMA-Assisted Psychotherapy Training Program appeared...
This has been a busy quarter for the psychedelic industry, particularly Lucy Scientific Discovery Inc. The company has announced three acquisitions in...
The company has plans to become a full-fledged psychedelics manufacturer. The post Optimi Health Gets Permission to Supply MDMA, Psilocybin to Medical...
Dr. Kozikowski is a leader in medicinal chemistry designing Novel Chemical Entities (NCEs) for oncology and neuroscience. The post PurMinds Appoints Leading...
From the desk of Nick Kadysh, Founding CEO, PharmAla Biotech “I just did my MDMA-assisted therapy yesterday. This modality is going to save so many lives....
On August 8th, 2023, Lucy Scientific Discovery Inc. (NASDAQ: LSDI), a leading developer in the psychedelic drug industry, witnessed an impressive surge...
Will PharmaTher be the next company to get a psychedelic medicine to market? The post PharmaTher Submits New Drug Application to the FDA appeared first...
Reset Pharma has licensed Filament’s botanical psilocybin drug candidate for a phase 2 clinical trial studying demoralization syndrome Filament Health...
Filament Health Corp. (OTCQB: FLHLF / NEO: FH / FSE: 7QS), a clinical-stage natural psychedelic drug development company, is pleased to announce an...